Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.
IPO Year:
Exchange: NASDAQ
Website: palisadebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/2/2022 | $5.00 | Buy | Ladenburg Thalmann |
| 8/31/2021 | $7.00 | Buy | Maxim Group |
Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202
424B3 - PALISADE BIO, INC. (0001357459) (Filer)
424B3 - PALISADE BIO, INC. (0001357459) (Filer)
424B3 - PALISADE BIO, INC. (0001357459) (Filer)
EFFECT - PALISADE BIO, INC. (0001357459) (Filer)
8-K - PALISADE BIO, INC. (0001357459) (Filer)
424B5 - PALISADE BIO, INC. (0001357459) (Filer)
POS AM - PALISADE BIO, INC. (0001357459) (Filer)
EFFECT - PALISADE BIO, INC. (0001357459) (Filer)
S-1/A - PALISADE BIO, INC. (0001357459) (Filer)
S-1/A - PALISADE BIO, INC. (0001357459) (Filer)
Ladenburg Thalmann initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00
Maxim Group initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00
Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 trial for the treatment of UC Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory and fibrotic diseases, today announced the completion of all five planned Single Ascending Dose (SAD) cohorts and the commencement of the Multiple Ascending Dose
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended. The Company approved the issuance of an option to purchase 2,600 shares of the Company's common stock to a new employee, as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The option was issued on January 3, 2025, and has an exercise price equi
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated mu
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class A Units with each unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the "Common Warrants"), and (ii) 3,120,688 Class B Uni
Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the pricing of an underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class A Units with each unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the "Common Warrants"), and (ii) 3,120,688 Class B Units with each unit cons
First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human clinical study for PALI-2108 for the treatment of Ulcerative Colitis (UC). The ongoing Phase 1 study is evaluating PALI-2108 in a single-center, double-blind, placebo-controlled study focused on safety, tolerability, p
Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn's disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preclinical results for PALI-2108, a novel local PDE4 inhibitor prodrug. In recent studies using the Dextran Sulfate Sodium (DSS) colitis mouse model, PALI-2108 demonstrated a dose-dependent effect on key fibrotic pathways, underscoring its
Presentation to highlight advances in fibrostenotic Crohn's Disease and the potential of localized PDE4 inhibition Carlsbad, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic disease, today announced that it has been invited to present at the 8th Annual Antifibrotic Drug Development (AFDD) Summit, being held November 19-21, 2024, in Boston, MA. Details of the presentation details are as follows: Title: Detailing Characteristics of Fibrostenotic Crohn's Disease Biology
Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the third quarter of 2024 and provided a business update. Recent Highlights Commenced enrollment and dosed first subjects in its Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-sev
Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it dosed its first subject in its Phase 1 clinical study of PALI-2108, an orally administered PDE4 inhibitor prodrug that is locally bioactivated in the colon and is in development for patients affected by UC. The Phase 1 study will evaluate PALI-2108 in a single-center, double-blind, placebo-controlled study focused on safety, tolerability, pharmacokinetics, and pharmacodynamics in healt
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated mu
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma
Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 20
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health SystemFlorian Rieder, MD, Associate Staff in the Department of Gastroenterology, Hepatology, and Nutrition, as well as an Investigator in the Department of Pathobiology at the Cleveland Clinic Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinic
Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer. Dr. Jones has a proven track record of successfully developing oral biotherapeutics and locally acting immunomodulating therapeutics designed to act locally within the gastrointestinal tract, including for inflammatory bowel disease. Throughout his career, Dr. Jones has established a reputation for not on
SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
4 - PALISADE BIO, INC. (0001357459) (Issuer)
SC 13G - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)